According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 Alvotech (NASDAQ: ALVO), a global biotech company...

The Annual and Extraordinary General Meeting (the "2023 AGM") of Alvotech (the "Company") was held on June 6, 2023 at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg.

The Board of Directors of Alvotech (the “Company”) resolved on June 6, 2023 to grant to certain members of the board a total of 109,524 shares through stock option agreements. The stock options will be granted to four independent board members.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...

Information related the press release issued on May 24, 2023 by Alvotech and Advanz Pharma with the heading "Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe".

Advanz Pharma secures exclusive rights from Alvotech to commercialize five proposed biosimilars in EuropeThe agreement includes proposed biosimilars to Simponi® (golimumab), Entyvio® (vedolizumab) and...

  Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022Confirmatory patient study for AVT05, a proposed biosimilar for Simponi®...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan...

Alvotech’s global workforce is now evenly split between females and males, and the unexplained gender pay gap has been reduced to 1.6% from 5.2% in December 2020Alvotech’s Equality Policy, which is...